10x Genomics Accounts Payable

10x Genomics (TXG) currently reports a accounts payable of $21M as of June 2026. That compares with $16M in the prior-year period — up 29.8% year over year. Use the charts on this page to explore 10x Genomics's accounts payable history and peer comparisons.

10x Genomics's accounts payable increased from $16M to $21M — a 29.8% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

10x Genomics reported $21M in accounts payable as of June 2026. That compares with $16M in the prior-year period — up 29.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $21M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for 10x Genomics, and consider following TXG for alerts when major investors trade the stock.

10x Genomics is classified in the Healthcare sector. On accounts payable, it currently shows $21M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TXG with unrelated industries.